粒子線治療市場 : 2028年までの世界予測

Report Overview

The global particle therapy market is projected to reach USD 1.1 billion by 2028 from USD 0.7 billion in 2023, growing at a CAGR of 8.2% during the forecast period. The projected surge in market growth for the Particle therapy market is seen due to an increase in cancers, advancements in technologies, and increased awareness among individuals regarding cancer, Increased funding for cancer research.

“The Paediatric application segment to register highest CAGR over the forecast period of 2023-2028.”
Based on the cancer type, the Particle therapy market is segmented into pediatric cancer, breast cancer, lung cancer, prostate cancer, head and neck, and other cancers. Pediatric cancer has witnessed the highest growth rate In 2022. The increase in Paediatric cancers can be seen due to the following reasons genetic predisposition, developmental factors in infants, immature immune system, environmental exposures, maternal factors, and cellular vulnerability among others.

“Asia Pacific to register significant growth rate in the market during the forecast period.”
For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for the particle therapy market. There are several drivers that contributed to this growth:
The maturing demographic profile observed in APAC countries accentuates the imperative for efficacious cancer treatment modalities characterized by minimized treatment-related adverse effects. This resonance with the precision-driven attributes of the Particle therapy market substantiates its pivotal role in enhancing the market landscape.
The incorporation of multilingual patient care offerings within APAC hospitals, combined with the accessibility to advanced treatments like the Particle therapy market, confers a unique allure to the region, particularly among a diverse patient spectrum. This fusion of linguistic inclusiveness and state-of-the-art medical interventions significantly enhances the region’s desirability as a favored healthcare destination, thereby fortifying its competitive position within the healthcare market landscape and concomitantly propelling the prominence of particle therapy market.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
• By Designation: C-level–27%, Director-level–18%, and Others–55%
• By Region: North America–50%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%

Prominent players in particle therapy market are Varian Medical Systems, Inc.(US), IBA Worldwide(EU) and  Hitachi (Japan) among others.

Research Coverage
• The report studies the Particle therapy market based on type, system, product, application, cancer type and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro markets with respect to their growth trends, prospects, and contributions to the global Particle therapy market.
• The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants/smaller firms in this market with investment evaluation viability within the Particle therapy market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, growth catalysts, challenges, and prospects, thereby empowering strategic decision-making with astute discernment.

The report provides insights on the following pointers:
• Analysis of key drivers (increasing prevalence of cancer patient population, Increasing  government initiatives for cancer management, advancements in non-invasive treatments through radiation therapy), restraints (Dearth of skilled radiologist/oncologist, high cost of particle therapy, Complexity of imaging technology for treatments), opportunities (Expansion of key players in emerging countries, Rising healthcare expenditure across developing countries), and challenges (Availability of alternative technology) influencing the growth of the Particle therapy market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the particle therapy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Particle therapy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Particle therapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Varian Medical Systems, Inc.(US), IBA Worldwide(EU) and  Hitachi (Japan) among others.

Table of Contents

1            INTRODUCTION            28

1.1         STUDY OBJECTIVES      28

1.2         MARKET DEFINITION   28

1.3         INCLUSIONS & EXCLUSIONS     29

1.4         MARKET SCOPE             29

1.4.1      MARKETS COVERED     29

1.4.2      REGIONS COVERED      30

1.4.3      YEARS CONSIDERED     30

1.4.4      CURRENCY CONSIDERED          31

TABLE 1             EXCHANGE RATES UTILIZED FOR CONVERSION TO USD              31

1.5         STAKEHOLDERS            31

1.6         SUMMARY OF CHANGES            31

1.6.1      RECESSION IMPACT: PARTICLE THERAPY MARKET       32

2            RESEARCH METHODOLOGY     33

2.1         RESEARCH DATA           33

FIGURE 1           RESEARCH DESIGN       33

2.1.1      SECONDARY DATA       33

2.1.1.1   Key data from secondary sources     34

2.1.2      PRIMARY DATA 35

2.1.2.1   Key primary sources           35

2.1.2.2   Key data from primary sources         36

2.1.2.3   Breakdown of primaries     36

FIGURE 2           BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 36

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION            37

2.1.2.4   Key industry insights          37

2.2         MARKET SIZE ESTIMATION       38

FIGURE 4           MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022              39

FIGURE 5           SUPPLY-SIDE ANALYSIS             39

FIGURE 6           TOP-DOWN APPROACH             40

FIGURE 7           CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES       41

FIGURE 8           CAGR PROJECTIONS     42

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    43

FIGURE 9           DATA TRIANGULATION METHODOLOGY         43

2.4         RESEARCH LIMITATIONS           44

2.4.1      SCOPE-RELATED LIMITATIONS             44

2.4.2      METHODOLOGY-RELATED LIMITATIONS         44

2.5         RISK ASSESSMENT         44

2.6         STUDY ASSUMPTIONS  45

2.6.1      IMPACT OF RECESSION ON PARTICLE THERAPY MARKET         45

3            EXECUTIVE SUMMARY 46

FIGURE 10         PARTICLE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)          46

FIGURE 11         PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)             47

FIGURE 12         PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)     47

FIGURE 13         PARTICLE THERAPY MARKET, BY SYSTEM, 2023 VS. 2028 (USD MILLION)          48

FIGURE 14         PARTICLE THERAPY MARKET, BY CANCER TYPE, 2023 VS. 2028 (USD MILLION) 49

FIGURE 15         PARTICLE THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 49

FIGURE 16         GEOGRAPHICAL SNAPSHOT OF PARTICLE THERAPY MARKET              50

4            PREMIUM INSIGHTS      51

4.1         PARTICLE THERAPY MARKET OVERVIEW          51

FIGURE 17         INCREASING PREVALENCE OF CANCER TO DRIVE MARKET              51

4.2         REGIONAL MIX: PARTICLE THERAPY MARKET  52

FIGURE 18         ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 52

4.3         ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE AND COUNTRY (2022)   53

FIGURE 19         PROTON THERAPY ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022  53

4.4         PARTICLE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           54

FIGURE 20         CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD              54

4.5         DEVELOPED VS. EMERGING ECONOMIES: PARTICLE THERAPY MARKET            54

FIGURE 21         EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD     54

5            MARKET OVERVIEW     55

5.1         INTRODUCTION            55

FIGURE 22         PARTICLE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    55

5.1.1      DRIVERS            56

5.1.1.1   Advantages of particle therapy over photon therapy     56

5.1.1.2   Growing prevalence of cancer          56

5.1.1.3   Rising adoption of particle therapy in clinical trials      57

5.1.1.4   Increasing number of particle therapy centers worldwide           57

5.1.1.5   Technological advancements           57

5.1.2      RESTRAINTS     58

5.1.2.1   Infrastructural challenges in healthcare facilities          58

5.1.2.2   Affordability and accessibility of treatments   58

5.1.2.3   Unfavorable reimbursement policies and limited insurance coverage for particle therapy  59

5.1.3      OPPORTUNITIES           59

5.1.3.1   Growth potential of emerging economies       59

5.1.4      CHALLENGES   60

5.1.4.1   Difficulties in visualizing tumors during particle therapy procedures        60

5.1.4.2   Potential for unwanted radiation exposure     60

5.2         ECOSYSTEM/MARKET MAP       61

FIGURE 23         PARTICLE THERAPY MARKET: ECOSYSTEM ANALYSIS  61

5.3         PRICING ANALYSIS        61

5.4         SUPPLY CHAIN ANALYSIS          62

FIGURE 24         SUPPLY CHAIN ANALYSIS: PARTICLE THERAPY MARKET              62

5.5         PATENT ANALYSIS        63

5.5.1      PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET              63

FIGURE 25         TOTAL PATENTS GRANTED FROM 2012–2022    64

FIGURE 26         TOP PATENT APPLICANTS IN PARTICLE THERAPY        64

FIGURE 27         TOP PATENT OWNERS IN PARTICLE THERAPY 65

5.6         VALUE CHAIN ANALYSIS            65

FIGURE 28         PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS              66

5.7         TECHNOLOGY ANALYSIS           66

5.8         KEY CONFERENCES & EVENTS IN 2023–2024       67

5.9         REGULATORY LANDSCAPE       68

TABLE 2             NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         68

TABLE 3             EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         68

TABLE 4             ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         69

TABLE 5             REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         69

TABLE 6             REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION             70

5.10       REIMBURSEMENT ANALYSIS     70

TABLE 7             MEDICAL REIMBURSEMENT CODES FOR PARTICLE THERAPY PROCEDURES IN US, 2022           70

5.11       TRADE ANALYSIS          71

TABLE 8             INSTALLED BASE OF RADIOTHERAPY DEVICES 71

5.12       PORTER’S FIVE FORCES ANALYSIS         71

TABLE 9             PARTICLE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS          71

5.12.1    THREAT OF NEW ENTRANTS    71

5.12.2    THREAT OF SUBSTITUTES         72

5.12.3    BARGAINING POWER OF SUPPLIERS     72

5.12.4    BARGAINING POWER OF BUYERS           72

5.12.5    DEGREE OF COMPETITION       72

5.13       KEY STAKEHOLDERS & BUYING CRITERIA          72

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         72

FIGURE 29         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS      72

TABLE 10           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%)             73

5.13.2    BUYING CRITERIA         73

FIGURE 30         KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS              73

TABLE 11           KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS              73

5.14       CASE STUDY ANALYSIS 74

TABLE 12           CASE STUDY: ENHANCING PATIENT SAFETY—RT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC)         74

5.15       TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS     74

FIGURE 31         EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 74

6            PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE             75

6.1         INTRODUCTION            76

TABLE 13           PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)     76

6.2         PRODUCTS       76

TABLE 14           PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 76

TABLE 15           PARTICLE THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)     77

6.2.1      CYCLOTRONS  77

6.2.1.1   Advantages offered by cyclotrons over other accelerators to drive market 77

TABLE 16           CYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION)              78

TABLE 17           NORTH AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          78

TABLE 18           EUROPE: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78

TABLE 19           ASIA PACIFIC: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79

TABLE 20           LATIN AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     79

6.2.2      SYNCHROTRONS           79

6.2.2.1   Increasing investments for development of synchrotron facilities to aid market growth   79

TABLE 21           SYNCHROTRONS MARKET, BY REGION, 2021–2028 (USD MILLION)          80

TABLE 22           NORTH AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          80

TABLE 23           EUROPE: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80

TABLE 24           ASIA PACIFIC: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     81

TABLE 25           LATIN AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          81

6.2.3      SYNCHROCYCLOTRONS            81

6.2.3.1   High space requirements to limit adoption     81

TABLE 26           SYNCHROCYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION)          82

TABLE 27           NORTH AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    82

TABLE 28           EUROPE: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          83

TABLE 29          ASIA PACIFIC: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          83

TABLE 30           LATIN AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    84

6.3         SERVICES          84

6.3.1      AVAILABILITY OF WIDE RANGE OF SERVICES TO PROPEL MARKET              84

TABLE 31           PARTICLE THERAPY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 84

TABLE 32           NORTH AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    85

TABLE 33           EUROPE: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    85

TABLE 34           ASIA PACIFIC: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    86

TABLE 35           LATIN AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    86

7            PARTICLE THERAPY MARKET, BY TYPE 87

7.1         INTRODUCTION            88

TABLE 36           PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)          88

7.2         PROTON THERAPY       88

7.2.1      GROWING ADOPTION AS PRIMARY TREATMENT FOR VARIOUS CANCER TYPES TO DRIVE MARKET       88

TABLE 37           PROTON THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)          89

7.3         HEAVY ION THERAPY   89

7.3.1      SLOWER GROWTH ATTRIBUTED TO EXPERIMENTAL PHASE ACROSS MANY REGIONS             89

TABLE 38           HEAVY ION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)          90

8            PARTICLE THERAPY MARKET, BY SYSTEM         91

8.1         INTRODUCTION            92

TABLE 39           PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)          92

8.2         MULTI-ROOM SYSTEMS             92

8.2.1      LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES TO DRIVE INTEREST AMONG END USERS             92

TABLE 40           PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION)       93

8.3         SINGLE-ROOM SYSTEMS            93

8.3.1      COMPACT STRUCTURE AND REDUCED CAPITAL COST TO PROPEL GROWTH          93

TABLE 41           PARTICLE THERAPY MARKET FOR SINGLE-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION)  94

9            PARTICLE THERAPY MARKET, BY APPLICATION            95

9.1         INTRODUCTION            96

TABLE 42           PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96

9.2         TREATMENT APPLICATIONS    96

9.2.1      INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTERS TO SUPPORT MARKET GROWTH   96

TABLE 43           PARTICLE THERAPY MARKET FOR TREATMENT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 97

9.3         RESEARCH APPLICATIONS        97

9.3.1      INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS TO PROVIDE GROWTH OPPORTUNITIES              97

TABLE 44           PARTICLE THERAPY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)  98

10          PARTICLE THERAPY MARKET, BY CANCER TYPE            99

10.1       INTRODUCTION            100

TABLE 45           PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 100

10.2       PEDIATRIC CANCER      100

10.2.1    INCREASING CASES OF PEDIATRIC CANCER TO PROPEL MARKET              100

TABLE 46           PARTICLE THERAPY MARKET FOR PEDIATRIC CANCER, BY REGION, 2021–2028 (USD MILLION)       101

10.3       PROSTATE CANCER      101

10.3.1    ADVANTAGES OFFERED BY PARTICLE THERAPY FOR TREATMENT OF PROSTATE CANCER TO DRIVE MARKET             101

TABLE 47           PARTICLE THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION)       102

10.4       LUNG CANCER 102

10.4.1    GROWING CLINICAL TESTING OF PROTON THERAPY FOR LUNG CANCER TO DRIVE MARKET     102

TABLE 48           PARTICLE THERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION)          102

10.5       BREAST CANCER            103

10.5.1    LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-EFFECTS TO INCREASE ADOPTION OF PARTICLE THERAPY 103

TABLE 49           PARTICLE THERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION)       103

10.6       HEAD & NECK CANCER 103

10.6.1    USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY TO SUPPORT MARKET GROWTH    103

TABLE 50           PARTICLE THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2021–2028 (USD MILLION)       104

10.7       OTHER CANCERS           104

TABLE 51           PARTICLE THERAPY MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION)       104

11          PARTICLE THERAPY MARKET, BY REGION         105

11.1       INTRODUCTION            106

TABLE 52           PARTICLE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)          106

11.2       NORTH AMERICA          106

11.2.1    NORTH AMERICA: RECESSION IMPACT 106

FIGURE 32         NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT              107

TABLE 53          NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          108

TABLE 54           NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)          108

TABLE 55           NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)   108

TABLE 56           NORTH AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)       109

TABLE 57           NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)          109

TABLE 58           NORTH AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)             109

TABLE 59           NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           110

11.2.2    US         110

11.2.2.1 Growing number of particle therapy centers to drive market growth        110

TABLE 60           US: MACROECONOMIC INDICATORS    111

TABLE 61           US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          111

TABLE 62           US: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)     111

11.2.3    CANADA            112

11.2.3.1 Government initiative to include particle therapy as treatment method to boost market   112

TABLE 63           CANADA: MACROECONOMIC INDICATORS       112

TABLE 64           CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       113

TABLE 65           CANADA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          113

11.3       EUROPE             113

11.3.1    EUROPE: RECESSION IMPACT   114

TABLE 66           EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     114

TABLE 67           EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 114

TABLE 68           EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       115

TABLE 69           EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          115

TABLE 70           EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 115

TABLE 71           EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)          116

TABLE 72           EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          116

11.3.2    GERMANY         116

11.3.2.1 Increasing research on proton and heavy ion therapy to drive market growth              116

TABLE 73           GERMANY: MACROECONOMIC INDICATORS     117

TABLE 74           GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       117

TABLE 75          GERMANY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          117

11.3.3    FRANCE             118

11.3.3.1 Increasing healthcare expenditure to support particle therapy product adoption              118

TABLE 76           FRANCE: MACROECONOMIC INDICATORS        118

TABLE 77           FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       119

TABLE 78           FRANCE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          119

11.3.4    UK         119

11.3.4.1 Increasing acceptance of particle therapy techniques in cancer treatment to support market growth       119

TABLE 79           UK: MACROECONOMIC INDICATORS    120

TABLE 80           UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          120

TABLE 81           UK: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)     121

11.3.5    ITALY   121

11.3.5.1 Increasing awareness activities to support market growth           121

TABLE 82           ITALY: MACROECONOMIC INDICATORS            121

TABLE 83           ITALY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          122

TABLE 84           ITALY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          122

11.3.6    SPAIN   122

11.3.6.1 Increasing number of conferences and government funding for cancer research to drive market        122

TABLE 85           SPAIN: MACROECONOMIC INDICATORS            123

TABLE 86           SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          124

TABLE 87           SPAIN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          124

11.3.7    REST OF EUROPE           124

TABLE 88           REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)   125

TABLE 89           REST OF EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)       125

11.4       ASIA PACIFIC    125

11.4.1    ASIA PACIFIC: RECESSION IMPACT        126

FIGURE 33         ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT              127

TABLE 90           ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          128

TABLE 91           ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)     128

TABLE 92           ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       128

TABLE 93           ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             129

TABLE 94           ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)     129

TABLE 95           ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)          129

TABLE 96           ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          130

11.4.2    JAPAN  130

11.4.2.1 Increasing use of heavy ion therapy for cancer treatment to propel market              130

TABLE 97           JAPAN: MACROECONOMIC INDICATORS            131

TABLE 98          JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          131

TABLE 99           JAPAN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          131

11.4.3    CHINA  132

11.4.3.1 High cancer burden to drive market 132

TABLE 100         CHINA: MACROECONOMIC INDICATORS           132

TABLE 101        CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          133

TABLE 102         CHINA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          133

11.4.4    INDIA   133

11.4.4.1 Improving research capabilities to support market growth          133

TABLE 103         INDIA: MACROECONOMIC INDICATORS            134

TABLE 104         INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          134

TABLE 105         INDIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          134

11.4.5    AUSTRALIA       135

11.4.5.1 Healthcare funding availability to boost market growth 135

TABLE 106         AUSTRALIA: MACROECONOMIC INDICATORS  135

TABLE 107         AUSTRALIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       135

TABLE 108         AUSTRALIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             136

11.4.6    SOUTH KOREA 136

11.4.6.1 Rising prevalence of cancer to drive market   136

TABLE 109         SOUTH KOREA: MACROECONOMIC INDICATORS          137

TABLE 110         SOUTH KOREA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       137

TABLE 111         SOUTH KOREA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             137

11.4.7    REST OF ASIA PACIFIC  138

TABLE 112         REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            138

TABLE 113         REST OF ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    138

11.5       LATIN AMERICA             139

11.5.1    LATIN AMERICA: RECESSION IMPACT   139

TABLE 114         LATIN AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          139

TABLE 115         LATIN AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)     140

TABLE 116         LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)   140

TABLE 117         LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             140

TABLE 118         LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)          141

TABLE 119         LATIN AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)             141

TABLE 120         LATIN AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           141

11.5.2    BRAZIL 142

11.5.2.1 Government initiates to propel market growth             142

TABLE 121         BRAZIL: MACROECONOMIC INDICATORS          142

TABLE 122         BRAZIL: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       143

TABLE 123         BRAZIL: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          143

11.5.3    MEXICO             143

11.5.3.1 Growing adoption of advanced medical technologies to drive market       143

TABLE 124         MEXICO: MACROECONOMIC INDICATORS        144

TABLE 125         MEXICO: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       144

TABLE 126         MEXICO: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          144

11.5.4    REST OF LATIN AMERICA          145

TABLE 127         REST OF LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            145

TABLE 128         REST OF LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    145

11.6       MIDDLE EAST & AFRICA             146

11.6.1    IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET     146

11.6.2    MIDDLE EAST & AFRICA: RECESSION IMPACT   146

TABLE 129         MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)             147

TABLE 130         MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            147

TABLE 131         MIDDLE EAST & AFRICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    147

TABLE 132         MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION)        148

TABLE 133         MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION)           148

TABLE 134         MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           148

12          COMPETITIVE LANDSCAPE       149

12.1       OVERVIEW        149

12.2       STRATEGIES ADOPTED BY KEY PLAYERS           150

FIGURE 34         KEY DEVELOPMENTS IN PARTICLE THERAPY MARKET 150

12.3       REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 151

FIGURE 35         REVENUE ANALYSIS OF TOP PLAYERS IN PARTICLE THERAPY MARKET            151

12.4       MARKET SHARE ANALYSIS         152

FIGURE 36         MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022            152

12.5       COMPANY EVALUATION MATRIX          153

12.5.1    STARS  153

12.5.2    EMERGING LEADERS    153

12.5.3    PERVASIVE PLAYERS     153

12.5.4    PARTICIPANTS 153

FIGURE 37         PARTICLE THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022    154

12.6       COMPETITIVE BENCHMARKING FOR KEY PLAYERS       155

12.6.1    PARTICLE THERAPY MARKET: COMPANY FOOTPRINT 155

TABLE 135         OVERALL COMPANY FOOTPRINT (10 COMPANIES)       155

TABLE 136         TYPE FOOTPRINT (10 COMPANIES)       155

TABLE 137         PRODUCT & SERVICE FOOTPRINT (10 COMPANIES)      156

TABLE 138         SYSTEM FOOTPRINT (10 COMPANIES)  157

TABLE 139         CANCER TYPE FOOTPRINT (10 COMPANIES)     157

TABLE 140         APPLICATION FOOTPRINT (10 COMPANIES)     158

TABLE 141         REGIONAL FOOTPRINT (10 COMPANIES)           159

12.7       STARTUP/SME EVALUATION MATRIX   160

12.7.1    PROGRESSIVE COMPANIES       160

12.7.2    RESPONSIVE COMPANIES          160

12.7.3    DYNAMIC COMPANIES 160

12.7.4    STARTING BLOCKS       160

FIGURE 38         PARTICLE THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022    161

12.7.5    COMPETITIVE BENCHMARKING FOR STARTUPS/SMES 162

TABLE 142         OVERALL COMPANY FOOTPRINT          162

TABLE 143         TYPE FOOTPRINT         162

TABLE 144         PRODUCT & SERVICE FOOTPRINT         162

TABLE 145         SYSTEM FOOTPRINT    163

TABLE 146         CANCER TYPE FOOTPRINT       163

TABLE 147         APPLICATION FOOTPRINT       163

TABLE 148         REGIONAL FOOTPRINT             163

12.8       COMPETITIVE SCENARIOS & TRENDS   164

12.8.1    PRODUCT LAUNCHES & APPROVALS    164

TABLE 149         PARTICLE THERAPY MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−AUGUST 2023)     164

12.8.2    DEALS  164

TABLE 150         PARTICLE THERAPY MARKET: DEALS (JANUARY 2020−AUGUST 2023)     164

12.8.3    OTHER DEVELOPMENTS           166

TABLE 151         PARTICLE THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2020−AUGUST 2023) 166

13          COMPANY PROFILES    167

13.1       KEY PLAYERS   167

(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*

13.1.1    IBA WORLDWIDE           167

TABLE 152         IBA WORLDWIDE: BUSINESS OVERVIEW             167

FIGURE 39         IBA WORLDWIDE: COMPANY SNAPSHOT (2022) 168

13.1.2    VARIAN MEDICAL SYSTEMS, INC.           172

TABLE 153         VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW              172

FIGURE 40         VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022)              173

13.1.3    HITACHI, LTD. 176

TABLE 154         HITACHI, LTD.: BUSINESS OVERVIEW   176

FIGURE 41         HITACHI, LTD.: COMPANY SNAPSHOT (2021)    177

13.1.4    MEVION MEDICAL SYSTEMS     179

TABLE 155         MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW       179

13.1.5    SUMITOMO HEAVY INDUSTRIES LTD.  182

TABLE 156         SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW              182

FIGURE 42         SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)   183

13.1.6    PROVISION HEALTHCARE, LLC 185

TABLE 157         PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW  185

13.1.7    TOSHIBA MEDICAL SYSTEMS CORPORATION   186

TABLE 158         TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW        186

FIGURE 43         TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022)          187

13.1.8    OPTIVUS PROTON THERAPY, INC.         188

TABLE 159         OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW              188

13.1.9    PROTOM INTERNATIONAL, INC.            189

TABLE 160         PROTOM INTERNATIONAL, INC.: BUSINESS OVERVIEW 189

13.1.10  ADVANCED ONCOTHERAPY PLC           190

TABLE 161         ADVANCED ONCOTHERAPY PLC: BUSINESS OVERVIEW              190

13.2       OTHER PLAYERS           191

13.2.1    DANFYSIK A/S  191

TABLE 162         DANFYSIK A/S: BUSINESS OVERVIEW    191

13.2.2    P-CURE, LTD.   192

TABLE 163         P-CURE, LTD.: BUSINESS OVERVIEW     192

13.2.3    PTW FREIBURG GMBH  193

TABLE 164         PTW FREIBURG GMBH: BUSINESS OVERVIEW   193

*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.

14          APPENDIX         194

14.1       DISCUSSION GUIDE      194

14.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             199

14.3       CUSTOMIZATION OPTIONS      201

14.4       RELATED REPORTS       201

14.5       AUTHOR DETAILS         202